Table 3. Multivariate Cox regression analysis with PFS and OS as endpoint.
| Factors | PFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Pretreatment serum CA125 level (<244 U/mL vs. ≥244 U/mL) | 0.922 | 0.457–1.860 | 0.820 | 0.578 | 0.259–1.292 | 0.182 |
| Ascitic fluid (positive vs. negative) | 1.110 | 0.883–3.566 | 0.107 | 1.111 | 0.511–2.414 | 0.790 |
| FIGO stage (advanced vs. early) | 10.165 | 4.513–22.894 | <0.001 | 14.323 | 4.744–43.240 | <0.001 |
| PD-L1 expression (high vs. low) | 1.970 | 1.039–3.737 | 0.038 | 3.032 | 1.285–7.153 | 0.011 |
| Tumor volume (<10 cm vs. ≥10 cm) | 0.928 | 0.069–1.248 | 0.621 | 0.752 | 0.513–1.102 | 0.144 |
| Residual disease (>1 cm vs. R0, ≤1 cm) | 1.063 | 0.566–1.999 | 0.849 | 1.767 | 0.824–3.787 | 0.143 |
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; R0, no visible residual disease.